Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Endocyte slides on vintafolide NSCLC update

October 12, 2013 12:12 AM UTC

Endocyte Inc. (NASDAQ:ECYT) fell $3.28 (24%) to $10.50 on Friday after announcing that a DSMB said vintafolide monotherapy is unlikely to be superior to docetaxel on the primary progression-free survi...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article